Dundee research explains drug resistance in ovarian cancer
The researchers discovered that a gene called ABCB1, which is known to play a role in resistance to the chemotherapy drug paclitaxel in ovarian cancers, also causes resistance to other ovarian cancer treatments.
Women with ovarian cancer are commonly treated with a combination of carboplatin and paclitaxel, but if their cancer stops responding, doctors need other options.
For many women, particularly those with faults in their BRCA genes, a new family of drugs called PARP inhibitors can be one of the next treatments offered to them via a clinical trial.
But when the scientists, based at the University of Dundee, treated chemotherapy-resistant ovarian cancer cells grown in the lab with certain PARP inhibitors, including olaparib** and rucaparib, they found the cells used ABCB1 to survive the treatment in the same way they do paclitaxel.
Interestingly, when the researchers treated the same cancer cells with two other types of PARP inhibitors, called veliparib and AZD2461, the cells weren’t resistant to these drugs.
Dr Gillian Smith who led the research at the University of Dundee said: “Drug resistance is a major complication for many ovarian cancer patients. Our study shows an important resistance mechanism which is common to drugs used routinely in the clinic and to new drugs which are being tested in clinical trials.”
The researchers also found that the paclitaxel chemotherapy-resistant cancer cells used ABCB1 to survive treatment with a different chemotherapy drug called doxorubicin, which is also offered to some women whose cancer has stopped responding.
Dr Smith added: “Increasing our understanding of resistance mechanisms will allow us to develop tests to spot drug resistance more easily and to make sure patients are given the most appropriate drugs. Understanding the biology of drug resistant cancers could also lead to the development of new treatments that block cancer’s escape, making them susceptible to therapy again.”
Around 600 women are diagnosed with ovarian cancer in Scotland every year and each year around 380 women die from the disease.
Nell Barrie, senior science information manager at Cancer Research UK, said: “This research increases our understanding of how drug resistance develops in ovarian cancer at a cellular level. It shows for the first time that the same mechanism that causes ovarian cancer to become resistant to paclitaxel also applies to some PARP inhibitors and other chemotherapy treatments. Further studies are now needed in patients to see whether some treatments will perform better than others at helping to control ovarian cancer.”
The study was funded by the Ninewells Cancer Campaign and the Melville Robertson Trust.
For media enquiries please contact the Cancer Research UK press office on +44 203 469 8300 or, out-of-hours, the duty press officer on +44 7050 264 059.
*Smith et al., ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells. British Journal of Cancer, 2016.
Notes to Editor
** Olaparib is given to some women to try and control their cancer when standard chemotherapy is no longer working for them.